Previous 10 | Next 10 |
The following slide deck was published by AVITA Medical, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: AVITA Medical, Inc. 2022 Q1 - Results - Earnings Call Presentation
AVITA Medical, Inc. (RCEL) Q1 2022 Earnings Conference Call May 12, 2022 04:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Mike Perry - Chief Executive Officer Michael Holder - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Ma...
AVITA Medical press release (NASDAQ:RCEL): Q1 GAAP EPS of -$0.38. Revenue of $7.54M (+7.4% Y/Y). 2022 Revenue Guidance: Commercial revenues in calendar year 2022 are projected to be approximately $30 million, excluding BARDA revenues, which represents a 20% increase year-over year. We project...
VALENCIA, Calif. and MELBOURNE, Australia, May 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “ Company ”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous sk...
VALENCIA, Calif. and MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multipl...
VALENCIA, Calif. and MELBOURNE, Australia, April 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet ...
VALENCIA, Calif. and MELBOURNE, Australia, April 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multi...
VALENCIA, Calif. and MELBOURNE, Australia, April 04, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple ...
VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet ...
Commercial-stage regenerative medicine company, Avita Medical (NASDAQ:RCEL), announced on Monday that the Biomedical Advanced Research and Development Authority (BARDA) amended its current contract with the firm. The modification is intended to support the company’s clinical work relat...
News, Short Squeeze, Breakout and More Instantly...
VALENCIA, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its second quarter 2024 financia...
VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the Joseph M. Still Burn Center at Doctors Hosp...
2024-06-02 14:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...